• President of the Scientific committee
• IMVACC program coordinator

After training in Medicine, Pediatrics, and Pediatric Allergy and Immunology at the Italian Universities of Brescia and Pavia, Prof. Candotti was granted a NIH Postdoctoral Fellowship in the laboratory of Dr. Michael Blaese at NCI and NHGRI before joining the Department of Pediatrics of the University of Brescia as an Assistant Professor in 1996 and eventually accepting a position at NHGRI that led to tenure at that institution in 2004. Ten years later, Prof. Candotti moved back to Europe to join the Division of Immunology and Allergy of the university Hospital of Lausanne in Switzerland, where he is Associate Professor of Medicine and Director of the Vaccine and Immunotherapy Center.

Throughout his career, Prof. Candotti focused on the study of the molecular basis of disorders of the immune system and the development gene therapy strategies for this heterogeneous group of diseases. He contributed to the discovery of JAK3-deficiency and AK2-deficiency as causes of SCID and performed extensive pre-clinical studies in the murine model supporting the feasibility of gene therapy for X-linked SCID and the Wiskott-Aldrich syndrome. From 2001 until 2014, Prof. Candotti co-led a series of gene therapy clinical trials for ADA-deficient SCID patients that studied the efficacy of different retroviral gene transfer vectors in humans.
Prof. Candotti has authored more than 110 peer-reviewed publications and numerous reviews and book chapters in the fields of immunodeficiency and gene therapy and is currently a member of the Editorial Board of the Journal of Clinical Immunology.

E-mail

• Academic Director
• SVRI representative
• CHUV representative
• Representative of the Faculty of Biology & Medicine Lausanne University 

Giuseppe Pantaleo, M.D., Professor of medicine, is Chief of the Division of Immunology and Allergy. He is also Chief of the Laboratory of AIDS Immunopathogenesis at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland. During the past ten years, Professor Pantaleo’s research has been focused on the delineation of the immunopathogenesis of HIV infection. His research activities have been focused on human T cell cloning, human T cell phenotypic and functional analysis, T cell activation, differentiation and memory, immunopathogenesis of HIV infection, HIV distribution in different anatomic compartments, antiretroviral therapy, immune reconstitution after antiretroviral therapy, immune-based therapeutic strategies and vaccines.

Professor Pantaleo is author and co-author of about 270 publications in international scientific journals.

E-mail

Vice-Dean for Education at the Faculty of Biology and Medicine, University of Lausanne, Lausanne, Vaud, Switzerland.

Associate Professor and Holder of the Chair of medicine for vulnerable populations at the University of Lausanne in Switzerland. Senior Physician and Chief of the Department of Vulnerabilities and Social Medicine at Unisanté, Lausanne.

E-mail

• Health Sciences eTraining (HSeT) Foundation representative

Jean-Pierre Kraehenbuhl, MD, is the Chief Executive Officer of the Health Sciences eTraining (HSeT) Foundation. He is emeritus Professor at the University of Lausanne and Consultant at the Division of Immunology & Allergy of the University Hospital (CHUV), Lausanne, Switzerland. His field of expertise is mucosal immunology and vaccinology. He is a member of EMBO and the scientific co-founder of Oravax, now Acambis Ltd.

Jean-Pierre Kraehenbuhl received an M.D. from the University of Lausanne, Switzerland in 1967 and a PhD in 1973. He completed a postdoctoral fellowship with George Palade at the Rockefeller University and subsequently became an assistant professor at Yale University School of Medicine. In 1975, he returned to the Institute of Biochemistry at the University of Lausanne, where he became a full professor in 1984. He joined the Swiss Institute of Cancer Research (ISREC) as a senior staff member, working on epithelial-cell membrane trafficking, mucosal immunity and mucosal vaccine design.

Health Sciences eTraining (HSeT) Foundation
Ch. des Boveresses 155
1066 Epalinges
CH – Switzerland

Phone +41 21 692 58 56
Fax +41 21 692 57 15

E-mail

• Representative of UNIL-EPFL Continuing Education Foundation

Dr. Pascale Dalla Piazza, Scientific officer at the UNIL-EPFL Continuing Education Foundation

University of Lausanne (UNIL) and Swiss Technology Institute Lausanne (EPFL)

E-mail

• President of the Scientific committee
• IMVACC program coordinator

After training in Medicine, Pediatrics, and Pediatric Allergy and Immunology at the Italian Universities of Brescia and Pavia, Prof. Candotti was granted a NIH Postdoctoral Fellowship in the laboratory of Dr. Michael Blaese at NCI and NHGRI before joining the Department of Pediatrics of the University of Brescia as an Assistant Professor in 1996 and eventually accepting a position at NHGRI that led to tenure at that institution in 2004. Ten years later, Prof. Candotti moved back to Europe to join the Division of Immunology and Allergy of the university Hospital of Lausanne in Switzerland, where he is Associate Professor of Medicine and Director of the Vaccine and Immunotherapy Center.

Throughout his career, Prof. Candotti focused on the study of the molecular basis of disorders of the immune system and the development gene therapy strategies for this heterogeneous group of diseases. He contributed to the discovery of JAK3-deficiency and AK2-deficiency as causes of SCID and performed extensive pre-clinical studies in the murine model supporting the feasibility of gene therapy for X-linked SCID and the Wiskott-Aldrich syndrome. From 2001 until 2014, Prof. Candotti co-led a series of gene therapy clinical trials for ADA-deficient SCID patients that studied the efficacy of different retroviral gene transfer vectors in humans.
Prof. Candotti has authored more than 110 peer-reviewed publications and numerous reviews and book chapters in the fields of immunodeficiency and gene therapy and is currently a member of the Editorial Board of the Journal of Clinical Immunology.

E-mail

2003 PhD–Biochemistry at European Molecular Biology Laboratory. Heidelberg, Germany.
2004-2006 Post-Doc–Biophysics at European Molecular Biology Laboratory. Heidelberg. Germany.
2006-2010 Research scientist at Novartis Institutes for BioMedical Research. United Kingdom.
2011-2020 Principal investigator. Institutes for Research Biomedicine. Switzerland.
2020-to date Professor (associate), Faculty of Biology and Medicine, University of Lausanne. Switzerland

E-mail

2007: Swiss Federal Medical Diploma, Faculty of Medicine, University of Geneva
2007-2011:  MD-PhD, Potential of T regulatory cells to protect pancreatic islet grafts, University of Geneva
2011-2014: Residency in internal medicine, University Hospital of Geneva
2014-2016: Residency in immunology and allergy
2016-2017, Residency in transplantation, University Hospital of Lausanne
2017- 2020, Postdoctoral fellowship on cell therapies engineering, University California, San Francisco (UCSF)
2020-ongoing, Senior attending physician in immunology and allergy, University Hospital of Lausanne,
2021-ongoing, Assistant Professor, tenure track, Faculty of Biology and Medicine, University of Lausanne

E-mail

Professors, Teachers, Professionals experts

Dr Ivana Knezevic is Scientist in Technologies, Standards and Norms Team, and Group Lead of Norms and Standards for Biologicals in the Department of Essential Medicines and Health Products (EMP) in the World Health Organization (WHO), Switzerland.

Dr Ivana Knezevic has 22 years of professional experience in standardization, scientific and regulatory overview of biologicals. She joined WHO Biological Standardization Programme in September 2000. Since 2006, she has been leading the team for standardization of vaccines and some biological therapeutics in WHO Headquarters. Main aspects of the work include development and establishment of WHO International Standards as well as the assistance to regulators, manufacturers and other users of these standards.

In the area of biotherapeutics, she coordinated the development of WHO’s Guidelines on evaluation of Similar Biotherapeutic Products (SBPs), and organized a series of workshops to facilitate the implementation of guiding principles for evaluation of biotherapeutic products into regulatory and manufacturers’ practices.

E-mail

• Health Sciences eTraining (HSeT) Foundation representative

Jean-Pierre Kraehenbuhl, MD, is the Chief Executive Officer of the Health Sciences eTraining (HSeT) Foundation. He is emeritus Professor at the University of Lausanne and Consultant at the Division of Immunology & Allergy of the University Hospital (CHUV), Lausanne, Switzerland. His field of expertise is mucosal immunology and vaccinology. He is a member of EMBO and the scientific co-founder of Oravax, now Acambis Ltd.

Jean-Pierre Kraehenbuhl received an M.D. from the University of Lausanne, Switzerland in 1967 and a PhD in 1973. He completed a postdoctoral fellowship with George Palade at the Rockefeller University and subsequently became an assistant professor at Yale University School of Medicine. In 1975, he returned to the Institute of Biochemistry at the University of Lausanne, where he became a full professor in 1984. He joined the Swiss Institute of Cancer Research (ISREC) as a senior staff member, working on epithelial-cell membrane trafficking, mucosal immunity and mucosal vaccine design.

Health Sciences eTraining (HSeT) Foundation
Ch. des Boveresses 155
1066 Epalinges
CH – Switzerland

Phone +41 21 692 58 56
Fax +41 21 692 57 15

E-mail